Evotec Announces Three-Year Drug Discovery Collaboration

Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------

Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ:
EVTC) today announced the start of a research collaboration with
Novartis to identify and develop novel small molecule therapeutics.
The collaboration will run for an initial period of three years.

Evotec will apply its powerful drug discovery platform in combination
with its extensive disease biology expertise to advance a drug
discovery program against a target nominated by Novartis through
discovery into the clinic. Furthermore, the agreement may be expanded
by the addition of a second program.

Under the terms of the agreement, Evotec will progress the programs
up to preclinical development and Novartis will then have the
responsibility for all clinical development activities, manufacture
and commercialization of the compounds. In return for Evotec's
contributions to the research program, Evotec is eligible for an
upfront payment, research funding as well as preclinical and clinical
milestone payments that could exceed $ 28 million. In addition,
Novartis will pay royalties on sales of any marketed products
resulting from the collaboration.

Jörn Aldag, President & Chief Executive Officer of Evotec, said: "We
are delighted that Novartis has chosen to collaborate with Evotec.
Novartis' decision to work with us is further recognition of our
track record in advancing compounds into the clinic. We are excited
to be leveraging our drug discovery expertise with such a world class
company."

Contact: Anne Hennecke, Senior Vice President, Investor Relations &
Corporate Communications, Evotec AG, Phone: +49.(0)40.56081-286,
anne.hennecke@evotec.com

Forward-Looking Statements
Information set forth in this press release contains forward-looking
statements, which involve a number of risks and uncertainties. Such
forward-looking statements include, but are not limited to,
statements about our expectations and assumptions concerning
regulatory, clinical and business strategies, the progress of our
clinical development programs and timing of the results of our
clinical trials, strategic collaborations and management's plans,
objectives and strategies. These statements are neither promises nor
guarantees, but are subject to a variety of risks and uncertainties,
many of which are beyond our control, and which could cause actual
results to differ materially from those contemplated in these
forward-looking statements. In particular, the risks and
uncertainties include, among other things: risks that product
candidates may fail in the clinic or may not be successfully marketed
or manufactured; risks relating to our ability to advance the
development of product candidates currently in the pipeline or in
clinical trials; our inability to further identify, develop and
achieve commercial success for new products and technologies;
competing products may be more successful; our inability to interest
potential partners in our technologies and products; our inability to
achieve commercial success for our products and technologies; our
inability to protect our intellectual property and the cost of
enforcing or defending our intellectual property rights; our failure
to comply with regulations relating to our products and product
candidates, including FDA requirements; the risk that the FDA may
interpret the results of our studies differently than we have; the
risk that clinical trials may not result in marketable products; the
risk that we may be unable to successfully secure regulatory approval
of and market our drug candidates; and risks of new, changing and
competitive technologies and regulations in the U.S. and
internationally.
The list of risks above is not exhaustive. Our Annual Report on Form
20-F, filed with the Securities and Exchange Commission, and other
documents filed with, or furnished to the Securities and Exchange
Commission, contain additional factors that could impact our
businesses and financial performance. We expressly disclaim any
obligation or undertaking to release publicly any updates or
revisions to any such statements to reflect any change in our
expectations or any change in events, conditions or circumstances on
which any such statement is based.

--- End of Message ---

Evotec AG
Schnackenburgallee 114 Hamburg Germany

WKN: 566480; ISIN:
DE0005664809 ; Index: Prime All Share, CDAX, HDAX, MIDCAP, TECH All
Share;
Listed: Geregelter Markt in Frankfurter Wertpapierbörse, Prime
Standard in Frankfurter Wertpapierbörse,
Freiverkehr in Börse Berlin, Freiverkehr in Bayerische Börse München,

Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Stuttgart,

Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr
in Niedersächsische Börse zu Hannover;
Copyright © Hugin AS 2008. All rights reserved.